Loteprednol etabonate ophthalmic suspension 0.5% had a market value of roughly $89 million for the 12 months ended February 2019, according to IQVIA data.
The Food and Drug Administration's approval of Ambrientan generics and their REMS programs provide patients with additional products to treat pulmonary arterial hypertension.